EUVIMEDEUVIMED entdecken
Crossref

Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders

Mutong Zhao iD, Yi Zhuang, Yuan Liang, Lin Ma, Chunping Shen

Clinical & Experimental Allergy · 2024

DOI: 10.1111/cea.14518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2024. Verfasst von Mutong Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Capital's Fund for Health Improvement and Research, Chinese Association of Rehabilitation Medicine's Fund for Technological Improvement, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDermatitis, AtopicAdolescentChildChild, PreschoolFemaleHumansMaleDrug ResistanceHeterocyclic Compounds, 3-RingTreatment Outcome

Stichwörter der Autor:innen

atopic dermatitisclinical immunologydermatologyepidemiologypediatrics

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabHeterocyclic Compounds, 3-Ringupadacitinib

Autor:innen und Institutionen

  • Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

ORCID-Profile: Mutong Zhao

Förderung

  • Capital's Fund for Health Improvement and Research
  • Chinese Association of Rehabilitation Medicine's Fund for Technological Improvement
  • Beijing Natural Science Foundation
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Zhao, M., Zhuang, Y., Liang, Y., Ma, L., & Shen, C. (2024). Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14518

Vancouver

Zhao M, Zhuang Y, Liang Y, Ma L, Shen C. Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14518

BibTeX
@article{Zhao2024,
  author = {Zhao, Mutong and Zhuang, Yi and Liang, Yuan and Ma, Lin and Shen, Chunping},
  title = {Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders},
  journal = {Clinical & Experimental Allergy},
  year = {2024},
  doi = {10.1111/cea.14518}
}
Kostenlos starten →